Alert detail
LCD L38292: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Palmetto GBA
What changed
New genomic assay coverage requires billing team review.
Who’s affected: Oncology billing teams · Effective: July 3, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 6 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.